High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma Journal Article


Authors: Murren, J. R.; DeRosa, W.; Durivage, H. J.; Davis, C.; Makuch, R.; Portlock, C. S.
Article Title: High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma
Abstract: The combination of cisplatin plus dacarbazine (DTIC) is active in metastatic melanoma with response rates reported between 10% and 55%. To optimize this regimen, a Phase II study was conducted employing a dose intensity of cisplatin higher than previously reported. Twenty‐two patients were treated. Eight patients received cisplatin 100 mg/m2 on days 1 and 8 combined with DTIC 300 mg/m2 on days 1, 2, 8, and 9 (regimen A). Because of excessive toxicity, the protocol was modified so that cisplatin was given at 50 mg/m2 per day and DTIC 350 mg/m2 per day on days 1 through 3 (regimen B). The overall response rate was 32% and consisted of four partial and three complete responses (CR). The median duration of response was 6 months. Two of the CR remain in sustained, unmaintained remission in excess of 1.5 years. All seven patients that responded were treated on regimen B. High‐dose cisplatin plus DTIC on a 3‐day schedule represents an effective, well‐tolerated therapy for metastatic melanoma. Copyright © 1991 American Cancer Society
Keywords: adult; clinical article; aged; survival rate; cisplatin; dacarbazine; melanoma; metastasis; nephrotoxicity; phase 2 clinical trial; bone marrow suppression; antineoplastic combined chemotherapy protocols; animal experiment; drug response; remission induction; intravenous drug administration; hematologic diseases; middle age; nervous system diseases; drug evaluation; kidney diseases; human; male; female; priority journal; article
Journal Title: Cancer
Volume: 67
Issue: 6
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 1991-03-15
Start Page: 1514
End Page: 1517
Language: English
DOI: 10.1002/1097-0142(19910315)67:6<1514::Aid-cncr2820670609>3.0.Co;2-q
PUBMED: 2001539
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 27 September 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Carol Portlock
    204 Portlock